Lamotrigine (All indications)

Nervous system anomalies

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S15197
R62328		 Cohen (Lamotrigine) (Mixed indications), 2023 Nervous system malformation 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 1.41 [0.88;2.27] -/8,339   -/4,866,362 - 8,339
ref
S8924
R48248		 Thomas (Lamotrigine) (Controls unexposed, sick), 2021 Neural malformations 1st trimester prospective cohort unexposed, sick Adjustment: No 6.86 [0.13;349.61] C 0/50   0/340 0 50
ref
S8969
R30377		 Ban (Lamotrigine) (Mixed indications), 2015 Nervous system anomaly 1st trimester prospective cohort unexposed (general population or NOS) Adjustment: No 1.28 [0.08;20.59] C 0/273   367/257,153 367 273
ref
Total 3 studies 1.44 [0.90;2.29] 367 8,662
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Cohen (Lamotrigine) (Mixed indications), 2023Cohen, 2023 1 1.41[0.88; 2.27]-8,33996%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Thomas (Lamotrigine) (Controls unexposed, sick), 2021Thomas, 2021 2 6.86[0.13; 349.61]0501%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Ban (Lamotrigine) (Mixed indications), 2015Ban, 2015 3 1.28[0.08; 20.59]3672733%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Total (3 studies) I2 = 0% 1.44[0.90; 2.29]3678,6620.520.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Lamotrigine) (Mixed indications; 2: Lamotrigine) (Controls unexposed, sick; 3: Lamotrigine) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.44[0.90; 2.29]3678,6620%NACohen (Lamotrigine) (Mixed indications), 2023 Thomas (Lamotrigine) (Controls unexposed, sick), 2021 Ban (Lamotrigine) (Mixed indications), 2015 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.41[0.88; 2.24]3678,6120%NACohen (Lamotrigine) (Mixed indications), 2023 Ban (Lamotrigine) (Mixed indications), 2015 2 unexposed, sickunexposed, sick 6.86[0.13; 349.61]-50 -NAThomas (Lamotrigine) (Controls unexposed, sick), 2021 1 Tags Adjustment   - No  - No 2.24[0.23; 21.64]3673230%NAThomas (Lamotrigine) (Controls unexposed, sick), 2021 Ban (Lamotrigine) (Mixed indications), 2015 2   - Yes  - Yes 1.41[0.88; 2.26]-8,339 -NACohen (Lamotrigine) (Mixed indications), 2023 1 All studiesAll studies 1.44[0.90; 2.29]3678,6620%NACohen (Lamotrigine) (Mixed indications), 2023 Thomas (Lamotrigine) (Controls unexposed, sick), 2021 Ban (Lamotrigine) (Mixed indications), 2015 30.520.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.41[0.88; 2.24]3678,6120%NACohen (Lamotrigine) (Mixed indications), 2023 Ban (Lamotrigine) (Mixed indications), 2015 2 unexposed, sick controlsunexposed, sick controls 6.86[0.13; 349.61]-50 -NAThomas (Lamotrigine) (Controls unexposed, sick), 2021 10.510.01.0